A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Summary

The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are: What is the safe dose of KQB365 by itself, in combination with cetuximab, or in combination with KQB198? Does KQB365 alone, in combination with cetuximab, or in combination with KQB198 decrease the size of the tumor? What happens to KQB365 in the body? Participants will: Receive KQB365 infusion weekly alone, in combination with cetuximab, or in combination with oral KQB198.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• KRAS G12C Mutation
• KRAS G12S Mutation
• Solid Tumor Malignancies
• CRC (Colorectal Cancer)
• NSCLC
• NSCLC (Non-small-cell Lung Cancer)
• NSCLC Non-small Cell Lung Cancer
• Lung Cancer (Non-Small Cell)
• KRAS G12-mutant NSCLC

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Kumquat Biosciences Inc.

Last updated on ClinicalTrials.gov

November 3, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites